BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 23901349)

  • 1. p300 Influences Butyrate-Mediated WNT Hyperactivation In Colorectal Cancer Cells.
    Lazarova DL; Wong T; Chiaro C; Drago E; Bordonaro M
    J Cancer; 2013; 4(6):491-501. PubMed ID: 23901349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CBP Activity Mediates Effects of the Histone Deacetylase Inhibitor Butyrate on WNT Activity and Apoptosis in Colon Cancer Cells.
    Lazarova DL; Chiaro C; Wong T; Drago E; Rainey A; O'Malley S; Bordonaro M
    J Cancer; 2013; 4(6):481-90. PubMed ID: 23901348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypothesis: Sam68 and Pygo2 mediate cell type-specific effects of the modulation of CBP-Wnt and p300-Wnt activities in Colorectal Cancer Cells.
    Bordonaro M
    J Cancer; 2021; 12(16):5046-5052. PubMed ID: 34234873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CREB-binding protein, p300, butyrate, and Wnt signaling in colorectal cancer.
    Bordonaro M; Lazarova DL
    World J Gastroenterol; 2015 Jul; 21(27):8238-48. PubMed ID: 26217075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of Wnt Activity and Cell Physiology by Butyrate in LT97 Microadenoma Cells.
    Lazarova D; Lee A; Wong T; Marian B; Chiaro C; Rainey C; Bordonaro M
    J Cancer; 2014; 5(3):203-13. PubMed ID: 24563675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of the Role of CBP- and p300-Mediated Wnt Signaling on Colonic Cells.
    Bordonaro M; Lazarova DL
    JMIR Res Protoc; 2016 May; 5(2):e66. PubMed ID: 27177606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Further analysis of p300 in mediating effects of Butyrate in Colorectal Cancer Cells.
    Bordonaro M
    J Cancer; 2020; 11(20):5861-5866. PubMed ID: 32922528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ZEB1 Mediates Drug Resistance and EMT in p300-Deficient CRC.
    Lazarova D; Bordonaro M
    J Cancer; 2017; 8(8):1453-1459. PubMed ID: 28638460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p300 Knockout Promotes Butyrate Resistance.
    Lazarova DL; Bordonaro M
    J Cancer; 2017; 8(17):3405-3409. PubMed ID: 29151923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypothesis: Retinoblastoma protein inactivation mediates effects of histone deacetylase inhibitor-induced Wnt hyperactivation in colorectal cancer cells.
    Bordonaro M
    J Cancer; 2020; 11(3):668-677. PubMed ID: 31942190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amlexanox and UPF1 Modulate Wnt Signaling and Apoptosis in HCT-116 Colorectal Cancer Cells.
    Bordonaro M; Lazarova D
    J Cancer; 2019; 10(2):287-292. PubMed ID: 30719122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncogenic and Receptor-Mediated Wnt Signaling Influence the Sensitivity of Colonic Cells to Butyrate.
    Bordonaro M
    J Cancer; 2023; 14(3):446-453. PubMed ID: 36860917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A switch from canonical to noncanonical Wnt signaling mediates drug resistance in colon cancer cells.
    Bordonaro M; Tewari S; Cicco CE; Atamna W; Lazarova DL
    PLoS One; 2011; 6(11):e27308. PubMed ID: 22073312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tcf3 and cell cycle factors contribute to butyrate resistance in colorectal cancer cells.
    Chiaro C; Lazarova DL; Bordonaro M
    Biochem Biophys Res Commun; 2012 Nov; 428(1):121-6. PubMed ID: 23063976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Butyrate induced changes in Wnt-signaling specific gene expression in colorectal cancer cells.
    Lazarova DL; Chiaro C; Bordonaro M
    BMC Res Notes; 2014 Apr; 7():226. PubMed ID: 24716727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperinduction of Wnt activity: a new paradigm for the treatment of colorectal cancer?
    Bordonaro M; Lazarova DL; Sartorelli AC
    Oncol Res; 2008; 17(1):1-9. PubMed ID: 18488710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The activation of beta-catenin by Wnt signaling mediates the effects of histone deacetylase inhibitors.
    Bordonaro M; Lazarova DL; Sartorelli AC
    Exp Cell Res; 2007 May; 313(8):1652-66. PubMed ID: 17359971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vimentin, colon cancer progression and resistance to butyrate and other HDACis.
    Lazarova DL; Bordonaro M
    J Cell Mol Med; 2016 Jun; 20(6):989-93. PubMed ID: 27072512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CREPT facilitates colorectal cancer growth through inducing Wnt/β-catenin pathway by enhancing p300-mediated β-catenin acetylation.
    Zhang Y; Wang S; Kang W; Liu C; Dong Y; Ren F; Wang Y; Zhang J; Wang G; To KF; Zhang X; Sung JJ; Chang Z; Yu J
    Oncogene; 2018 Jun; 37(26):3485-3500. PubMed ID: 29563608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Butyrate and Wnt signaling: a possible solution to the puzzle of dietary fiber and colon cancer risk?
    Bordonaro M; Lazarova DL; Sartorelli AC
    Cell Cycle; 2008 May; 7(9):1178-83. PubMed ID: 18418037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.